EA003584B1 - Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства - Google Patents

Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства Download PDF

Info

Publication number
EA003584B1
EA003584B1 EA200100041A EA200100041A EA003584B1 EA 003584 B1 EA003584 B1 EA 003584B1 EA 200100041 A EA200100041 A EA 200100041A EA 200100041 A EA200100041 A EA 200100041A EA 003584 B1 EA003584 B1 EA 003584B1
Authority
EA
Eurasian Patent Office
Prior art keywords
paroxetine
core
pharmaceutically acceptable
acceptable salt
smoking
Prior art date
Application number
EA200100041A
Other languages
English (en)
Russian (ru)
Other versions
EA200100041A1 (ru
Inventor
Мартин Кс. Стейнер
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA200100041A1 publication Critical patent/EA200100041A1/ru
Publication of EA003584B1 publication Critical patent/EA003584B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200100041A 1998-06-16 1999-06-16 Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства EA003584B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (2)

Publication Number Publication Date
EA200100041A1 EA200100041A1 (ru) 2001-06-25
EA003584B1 true EA003584B1 (ru) 2003-06-26

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100041A EA003584B1 (ru) 1998-06-16 1999-06-16 Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства

Country Status (20)

Country Link
EP (1) EP1087766A4 (ja)
JP (1) JP2002518330A (ja)
KR (1) KR20010052895A (ja)
CN (1) CN1305379A (ja)
AP (1) AP2000002002A0 (ja)
AU (1) AU740749B2 (ja)
BG (1) BG105127A (ja)
BR (1) BR9911150A (ja)
CA (1) CA2335236A1 (ja)
CZ (1) CZ20004698A3 (ja)
EA (1) EA003584B1 (ja)
GB (1) GB9812941D0 (ja)
HU (1) HUP0102507A3 (ja)
IL (1) IL139943A0 (ja)
NO (1) NO20006383D0 (ja)
NZ (1) NZ508532A (ja)
PL (1) PL345261A1 (ja)
SK (1) SK19192000A3 (ja)
WO (1) WO1999065491A1 (ja)
ZA (1) ZA200007396B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
IL162458A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
HUP0102507A3 (en) 2003-12-29
PL345261A1 (en) 2001-12-03
HUP0102507A2 (hu) 2002-05-29
JP2002518330A (ja) 2002-06-25
ZA200007396B (en) 2002-02-27
SK19192000A3 (sk) 2001-05-10
AP2000002002A0 (en) 2000-12-31
CA2335236A1 (en) 1999-12-23
CN1305379A (zh) 2001-07-25
BR9911150A (pt) 2001-03-06
NO20006383L (no) 2000-12-14
EP1087766A1 (en) 2001-04-04
AU740749B2 (en) 2001-11-15
KR20010052895A (ko) 2001-06-25
NO20006383D0 (no) 2000-12-14
CZ20004698A3 (cs) 2002-02-13
NZ508532A (en) 2003-08-29
AU4688599A (en) 2000-01-05
EA200100041A1 (ru) 2001-06-25
BG105127A (en) 2001-11-30
EP1087766A4 (en) 2001-11-21
GB9812941D0 (en) 1998-08-12
WO1999065491A1 (en) 1999-12-23
IL139943A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
US6218421B1 (en) Method of promoting smoking cessation
KR101890450B1 (ko) Ｃｎｓ 장애의 치료에 사용되는 브렉스피프라졸 또는 이의 염 및 2 차 약물을 포함하는 조합물
RU2201754C2 (ru) Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности
EA003508B1 (ru) Композиции с контролируемым высвобождением пароксетина
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
EP0550083B1 (en) Medicaments for treating inflammatory conditions or for analgesia containing a NSAID and ranitidine bismuth citrate
EA014707B1 (ru) Новая форма введения рацекадотрила
JP3905386B2 (ja) 肥大を伴う心筋疾患の治療における徐脈剤の使用及び新規医薬組成物
BG104568A (bg) Фармацевтичен състав, съдържащ сибутрамин и орлистат
FR2904774A1 (fr) Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent.
CA2081344C (en) Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
US6300343B1 (en) Method of treatment
EA003584B1 (ru) Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
AU2003224419A1 (en) Orally administrable pharmaceutical formulation
JP2665357B2 (ja) 心不全治療用医薬組成物
KR20010105418A (ko) 기분 장애 치료용 오사네턴트
US4189492A (en) Antihypertensive compositions of 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole and N-(2-chloroethyl)-N-(1-methyl-2-phenoxy-ethyl)benzenemethanamine
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
CN101190890B (zh) 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
JPS60202812A (ja) ブロモクリプチン組成物
MXPA00012626A (en) Method of treatment
CA3222959A1 (en) Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists
JPH0827000A (ja) 悪阻による諸症状の予防または治療薬
JPH01250319A (ja) 医薬
JPH047323B2 (ja)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU